Absci Corporation ABSI External preclinical and clinical development — R&D

Other product segments

Similar metrics at other companies

RAPPPreclinical Programs External Expenses — Research And Development Expense

$4.29M+32.1%

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

ZYMEExpense for other preclinical and research programs — R&D

$7.26M+19.6%

MPLTPreclinical Program — Research And Development Expense

$5.52M-9.2%

NRIXInternal research and development expenses — R&D

$57.07M+12.2%

SRRKEarly Research — Research And Development Expense

$1.21M-16.8%

Questions, answered.

What is Absci Corporation's external preclinical and clinical development — R&D?

Absci Corporation (ABSI) reported external preclinical and clinical development — R&D of $4.29M in Q1 2026.

How has Absci Corporation's external preclinical and clinical development — R&D changed year-over-year?

Absci Corporation's external preclinical and clinical development — R&D increased by 59.7% year-over-year, from $2.68M to $4.29M.

What does external preclinical and clinical development — R&D mean?

This metric represents the direct research and development expenditures allocated to the external preclinical and clinical development segment. It captures the investment required to advance biologic drug candidates through experimental validation and early-stage clinical trials. Monitoring this spend provides insight into the company's commitment to scaling its proprietary therapeutic pipeline and the associated costs of externalizing development activities.